表紙
市場調查報告書

關注市場分析:急性淋巴性白血病 (ALL)

Market Spotlight: Acute Lymphoblastic Leukemia (ALL)

出版商 Datamonitor Healthcare 商品編碼 917493
出版日期 內容資訊 英文 56 Pages
商品交期: 最快1-2個工作天內
價格
Back to Top
關注市場分析:急性淋巴性白血病 (ALL) Market Spotlight: Acute Lymphoblastic Leukemia (ALL)
出版日期: 2019年10月31日內容資訊: 英文 56 Pages
簡介

本報告提供急性淋巴性白血病 (ALL的)治療藥市場相關分析,疾病概要和患者數的變化、預測,目前的主要的治療方法,法規環境和近幾年主要的事件,現在開發中臨床實驗的進展上市計劃,主要的治療藥的市場趨勢預測,資本交易的動向等調查。

概要

要點

疾病的背景情況

  • 定義
  • 患者區分
  • 症狀
  • 風險因素
  • 診斷

治療方法

  • 化療
  • 皮質類固醇
  • TKI療法
  • 免疫療法
  • 放射線治療
  • 幹細胞移植

流行病學

已上市醫藥品

開發平台藥物

最新活動、分析師的見解

  • Blincyto
  • Copiktra
  • KTE-X19
  • Copiktra
  • Marqibo
  • AFM11
  • KTE-X19
  • AUTO3
  • Xpovio
  • AFM11
  • ERY-ASP
  • KTE-X19

不久將來的活動

法規相關的主要活動

成功的可能性

授權合約、資產收購交易

母體專利

商機

臨床實驗形勢

  • 贊助商數:各狀態
  • 贊助商數:各階段 (相位)
  • 近幾年趨勢

相關分析

  • 處方藥的資訊

附錄

目錄
Product Code: DMKC0207213

This Market Spotlight report covers the Acute Lymphoblastic Leukemia (ALL) market, comprising key marketed and pipeline drugs, clinical trials, recent events and analyst opinion, regulatory events, probability of success, patent information, a 10-year disease incidence forecast, and licensing and acquisition deals, as well as presenting drug-specific revenue forecasts.

Key Takeaways

Datamonitor Healthcare estimates that in 2018, there were 86,600 incident cases of ALL worldwide, and expects that number to increase to 93,500 incident cases by 2027.

Approved drugs in the ALL space focus on a wide variety of targets. The majority of these therapies are administered via the intravenous route, with the remaining products being available in oral and intramuscular formulations.

The greatest proportion of industry-sponsored drugs in active clinical development for ALL are in Phase I, with only one drug in Phase III.

Therapies in development for ALL focus on a wide variety of targets. The majority of pipeline drugs in development are administered via the intravenous route, with the remainder being tested in oral formulations.

The only high-impact upcoming event for drugs in the ALL space is topline Phase II trial results for Isatuximab. The overall likelihood of approval of a Phase I hematologic asset is 9.6%, and the average probability a drug advances from Phase III is 58.3%. Drugs, on average, take 8.8 years from Phase I to approval, compared to 9.3 years in the overall oncology space.

There have been 40 licensing and asset acquisition deals involving ALL drugs during 2014-19. The $1,220m strategic collaboration agreement signed in 2018 between Fate Therapeutics and Ono Pharmaceutical for the joint development and commercialization of two off-the-shelf CAR-T cell product candidates was the largest deal.

The distribution of clinical trials across Phase I-IV indicates that the vast majority of trials for ALL have been in the early and mid-phases of development, with 91% of trials in Phase I-II, and only 9% in Phase III-IV.

The US has a substantial lead in the number of ALL clinical trials globally. France leads the major EU markets, while China has the top spot in Asia.

Clinical trial activity in the ALL space is dominated by completed trials. Novartis has the highest number of completed clinical trials for ALL, with 41 trials.

Novartis leads industry sponsors with the highest overall number of clinical trials for ALL.

TABLE OF CONTENTS

OVERVIEW

KEY TAKEAWAYS

DISEASE BACKGROUND

  • Definition
  • Patient segmentation
  • Symptoms
  • Risk factors
  • Diagnosis

TREATMENT

  • Chemotherapy
  • Corticosteroids
  • TKI therapy
  • Immunotherapy
  • Radiation therapy
  • Stem cell transplant

EPIDEMIOLOGY

MARKETED DRUGS

PIPELINE DRUGS

RECENT EVENTS AND ANALYST OPINION

  • Blincyto for ALL (September 24, 2019)
  • Copiktra for ALL (July 25, 2019)
  • KTE-X19 for ALL (June 1, 2019)
  • Copiktra for ALL (March 6, 2019)
  • Marqibo for ALL (January 17, 2019)
  • AFM11 for ALL (December 3, 2018)
  • KTE-X19 for ALL (December 3, 2018)
  • AUTO3 for ALL (December 2, 2018)
  • Xpovio for ALL (December 1, 2018)
  • AFM11 for ALL (October 8, 2018)
  • ERY-ASP for ALL (June 24, 2018)
  • KTE-X19 for ALL (June 4, 2018)

KEY UPCOMING EVENTS

KEY REGULATORY EVENTS

  • Japan Approvals Include World-First For Skyrizi, Kymriah As Asia's First CAR-T
  • Measuring 'Minimal Residual Disease' With NGS

PROBABILITY OF SUCCESS

LICENSING AND ASSET ACQUISITION DEALS

  • CASI Acquires Global Rights To Juventas' Anti-CD19 Therapy

PARENT PATENTS

REVENUE OPPORTUNITY

CLINICAL TRIAL LANDSCAPE

  • Sponsors by status
  • Sponsors by phase
  • Recent events

BIBLIOGRAPHY

  • Prescription information

APPENDIX

LIST OF FIGURES

  • Figure 1: Trends in incident cases of ALL, 2018-27
  • Figure 2: Overview of pipeline drugs for ALL in the US
  • Figure 3: Pipeline drugs for ALL, by company
  • Figure 4: Pipeline drugs for ALL, by drug type
  • Figure 5: Pipeline drugs for ALL, by classification
  • Figure 6: Blincyto for ALL (September 24, 2019): Phase III - Pediatric (1st Relapse)
  • Figure 7: KTE-X19 for ALL (June 1, 2019): Phase I/II - ZUMA-3 (r/r Adults)
  • Figure 8: KTE-X19 for ALL (December 3, 2018): Phase I/II - ZUMA-3 (r/r Adults)
  • Figure 9: KTE-X19 for ALL (June 4, 2018): Phase I/II - ZUMA-3 (r/r Adults)
  • Figure 10: Key upcoming events in ALL
  • Figure 11: Probability of success in the ALL pipeline
  • Figure 12: Licensing and asset acquisition deals in ALL, 2014-19
  • Figure 13: Parent patents in ALL
  • Figure 14: Clinical trials in ALL
  • Figure 15: Top 10 drugs for clinical trials in ALL
  • Figure 16: Top 10 companies for clinical trials in ALL
  • Figure 17: Trial locations in ALL
  • Figure 18: ALL trials sponsors by status
  • Figure 19: ALL trials sponsors, by phase

LIST OF TABLES

  • Table 1: Incident cases of ALL, 2018-27
  • Table 2: Marketed drugs for ALL
  • Table 3: Pipeline drugs for ALL in the US
  • Table 4: Blincyto for ALL (September 24, 2019)
  • Table 5: Copiktra for ALL (July 25, 2019)
  • Table 6: KTE-X19 for ALL (June 1, 2019)
  • Table 7: Copiktra for ALL (March 6, 2019)
  • Table 8: Marqibo for ALL (January 17, 2019)
  • Table 9: AFM11 for ALL (December 3, 2018)
  • Table 10: KTE-X19 for ALL (December 3, 2018)
  • Table 11: AUTO3 for ALL (December 2, 2018)
  • Table 12: Xpovio for ALL (December 1, 2018)
  • Table 13: AFM11 for ALL (October 8, 2018)
  • Table 14: ERY-ASP for ALL (June 24, 2018)
  • Table 15: KTE-X19 for ALL (June 4, 2018)
  • Table 16: Historical global sales, by drug ($m), 2014-18
  • Table 17: Forecasted global sales, by drug ($m), 2019-23
Back to Top